Associated equity: BB Biotech
BB Biotech, a Swiss-based investment company, targets long-term capital growth from biotechnology companies developing and marketing innovative drugs. At least 90% of the portfolio is held in listed companies, primarily those that already have products on the market or promising drug candidates in advanced stages of development. BION is benchmarked against the Nasdaq Biotech Index (in CHF) but is managed on a bottom-up basis, with a focused c 20–35 stock portfolio.
BB Biotech — 9 videos in collection
In this interview, we speak to Dr Christian Koch, deputy head of investment management at BB Biotech (BION), the Switzerland-based investment company listed in Switzerland, Germany and Italy. Dr Koch will assume the role of head of investment management at BB Biotech at the beginning of 2025.
Dr Koch discusses the reasons for the improvement in investor sentiment regarding the biotech sector over the past year. He provides detail on some major milestones on the horizon for BB Biotech’s holdings and explains how the team’s data scientists are using big data and AI to enhance every aspect of the investment process and provide novel insights into developments in the sector.